De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Surmodics Toekomstige groei
Future criteriumcontroles 1/6
De verwachting is dat Surmodics de winst en omzet met respectievelijk 52.3% en 11% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 52.1% per jaar.
Belangrijke informatie
52.3%
Groei van de winst
52.1%
Groei van de winst per aandeel
Medical Equipment winstgroei | 17.6% |
Inkomstengroei | 11.0% |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | Low |
Laatst bijgewerkt | 14 Aug 2024 |
Recente toekomstige groei-updates
Recent updates
There's Reason For Concern Over Surmodics, Inc.'s (NASDAQ:SRDX) Massive 29% Price Jump
Jun 06Is Now The Time To Look At Buying Surmodics, Inc. (NASDAQ:SRDX)?
May 30Surmodics (NASDAQ:SRDX) Is Experiencing Growth In Returns On Capital
May 02We Think Surmodics (NASDAQ:SRDX) Can Stay On Top Of Its Debt
Sep 17News Flash: Analysts Just Made A Notable Upgrade To Their Surmodics, Inc. (NASDAQ:SRDX) Forecasts
Jun 26An Intrinsic Calculation For Surmodics, Inc. (NASDAQ:SRDX) Suggests It's 27% Undervalued
Jun 22Is Surmodics (NASDAQ:SRDX) A Risky Investment?
May 14Market Participants Recognise Surmodics, Inc.'s (NASDAQ:SRDX) Revenues Pushing Shares 36% Higher
Apr 17Shareholders May Be Wary Of Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation Package
Feb 03Surmodics (NASDAQ:SRDX) Has Debt But No Earnings; Should You Worry?
Jan 08Surmodics gets additional $125M in credit facility
Oct 17Surmodics Non-GAAP EPS of -$0.34 beats by $0.04, revenue of $24.9M misses by $0.29M
Jul 27Estimating The Intrinsic Value Of Surmodics, Inc. (NASDAQ:SRDX)
Jul 22Is It Too Late To Consider Buying Surmodics, Inc. (NASDAQ:SRDX)?
May 03Shareholders May Not Be So Generous With Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation And Here's Why
Feb 04Do Surmodics's (NASDAQ:SRDX) Earnings Warrant Your Attention?
Dec 24Estimating The Fair Value Of Surmodics, Inc. (NASDAQ:SRDX)
Aug 13Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
9/30/2026 | 154 | 2 | 26 | N/A | 2 |
9/30/2025 | 138 | -6 | 15 | N/A | 3 |
9/30/2024 | 123 | -13 | -10 | N/A | 3 |
6/30/2024 | 121 | -1 | -6 | -2 | N/A |
3/31/2024 | 143 | 14 | 23 | 26 | N/A |
12/31/2023 | 138 | 6 | 10 | 13 | N/A |
9/30/2023 | 133 | -2 | 8 | 11 | N/A |
6/30/2023 | 131 | -23 | 4 | 7 | N/A |
3/31/2023 | 103 | -36 | -26 | -23 | N/A |
12/31/2022 | 102 | -32 | -25 | -21 | N/A |
9/30/2022 | 100 | -27 | -21 | -17 | N/A |
6/30/2022 | 98 | -13 | -19 | -14 | N/A |
3/31/2022 | 97 | -10 | -13 | -8 | N/A |
12/31/2021 | 106 | 2 | 8 | 13 | N/A |
9/30/2021 | 105 | 4 | 9 | 15 | N/A |
6/30/2021 | 104 | 2 | 11 | 16 | N/A |
3/31/2021 | 107 | 7 | 20 | 24 | N/A |
12/31/2020 | 95 | 1 | 6 | 11 | N/A |
9/30/2020 | 95 | 1 | 10 | 14 | N/A |
6/30/2020 | 103 | 8 | 20 | 25 | N/A |
3/31/2020 | 101 | 7 | 7 | 13 | N/A |
12/31/2019 | 100 | 6 | 6 | 13 | N/A |
9/30/2019 | 100 | 8 | 1 | 8 | N/A |
6/30/2019 | 92 | 2 | -6 | 0 | N/A |
3/31/2019 | 90 | -2 | -11 | 3 | N/A |
12/31/2018 | 87 | -2 | 13 | 28 | N/A |
9/30/2018 | 81 | -4 | 20 | 34 | N/A |
6/30/2018 | 78 | -2 | 23 | 36 | N/A |
3/31/2018 | 74 | 1 | N/A | 37 | N/A |
12/31/2017 | 72 | 0 | N/A | 13 | N/A |
9/30/2017 | 73 | 4 | N/A | 14 | N/A |
6/30/2017 | 71 | 6 | N/A | 14 | N/A |
3/31/2017 | 73 | 9 | N/A | 20 | N/A |
12/31/2016 | 73 | 10 | N/A | 21 | N/A |
9/30/2016 | 71 | 10 | N/A | 25 | N/A |
6/30/2016 | 71 | 9 | N/A | 22 | N/A |
3/31/2016 | 67 | 9 | N/A | 18 | N/A |
12/31/2015 | 64 | 11 | N/A | 16 | N/A |
9/30/2015 | 62 | 12 | N/A | 15 | N/A |
6/30/2015 | 60 | 13 | N/A | 18 | N/A |
3/31/2015 | 59 | 13 | N/A | 19 | N/A |
12/31/2014 | 58 | 12 | N/A | 19 | N/A |
9/30/2014 | 57 | 12 | N/A | 18 | N/A |
6/30/2014 | 56 | 13 | N/A | 18 | N/A |
3/31/2014 | 56 | 13 | N/A | 17 | N/A |
12/31/2013 | 56 | 14 | N/A | 16 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat SRDX de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat SRDX de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat SRDX de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van SRDX ( 11% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.7% per jaar).
Hoge groei-inkomsten: De omzet van SRDX ( 11% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van SRDX naar verwachting over 3 jaar hoog zal zijn